Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Director | June 18, 2026 | June 23, 2026 |
| CITIGROUP INCC · Entity 2837 | Director | April 01, 2019 | April 02, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 95,400 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 95,400 · Balance 95,400 F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.
CITIGROUP INC
Report date April 01, 2019 · Filed April 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 21,304.0024 |
Reported balance
After 2019-04-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-04-01 · Grant · Acquired 151.3481 · Balance 21,304.0024 F1: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. |
| Common StockSEC Table I · non-derivative | Direct | 2,668.8124 |
Reported balance
After 2019-04-01 transaction · row 2
1 source rowRow 2 · 2019-04-01 · Grant · Acquired 14.6923 · Balance 2,668.8124 F1: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors.
F2: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kite Pharma, Inc.
Report date October 03, 2017 · Filed October 05, 2017
Section 16 reporting ended · disclosed 2017-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-10-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-10-03 · Other · Disposed 4,624 · Balance 1,807 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Row 2 · 2017-10-03 · Disposition to issuer · Disposed 1,807 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.12 · Expires 2025-09-08 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F4: This option provided for vesting in 36 equal monthly installments commencing October 9, 2015. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.87 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-03 · Disposition to issuer · Disposed 7,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F6: This option provided for vesting in 12 equal monthly installments following June 1, 2016. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.21 · Expires 2027-06-19 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-03 · Disposition to issuer · Disposed 8,810 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F7: This option provided for vesting in 12 equal monthly installments following June 20, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes.
F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit.
F4: This option provided for vesting in 36 equal monthly installments commencing October 9, 2015.
F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option.
F6: This option provided for vesting in 12 equal monthly installments following June 1, 2016.
F7: This option provided for vesting in 12 equal monthly installments following June 20, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 20:28 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantRestricted Stock Unit · Derivative | 95,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001548072-26-000002 · wk-form4_1782246485.xml · derivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires not disclosed F1 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. F1 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. F1 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 01:03 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantRestricted Stock Unit · Derivative | 95,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-25-000075 · wk-form4_1750727017.xml · derivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires not disclosed F1 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. F1 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. F1 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 21:05 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 9,221 | $2.16 | $19,917.36 |
DisclosureSEC source: 0001737287-24-000079 · wk-form4_1733778343.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,507 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices raging from $2.145 to $2.185, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:30 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 95,541 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001593968-24-000838 · primary_01.xml · derivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,541 Underlying: Common Stock · 95,541 shares Expires 2034-06-05 F1 · derivative.exercise_date: Vesting in 12 equal monthly installments Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:30 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 61,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000838 · primary_01.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,728 Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 11,200 | $2.34 | $26,181.12 |
DisclosureSEC source: 0001593968-24-000783 · primary_01.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,253 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.31 to $2.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:01 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 74,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-001010 · primary_01.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,453 Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:58 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 44,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-008172 · marketforms-56491.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,892 Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 21:45 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 16,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-006499 · marketforms-53111.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,714 Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:05 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 9,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005495 · marketforms-49011.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,216 Read SEC document |
| June 06, 2019 Filed Jun 25, 2019 00:01 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 16,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038864 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,247 Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 14.6923 | $63.05 | $926.35 |
DisclosureSEC source: 0001209191-19-022343 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,668.8124 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 151.3481 | $63.05 | $9,542.50 |
DisclosureSEC source: 0001209191-19-022343 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 21,304.0024 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 21:53 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 600.692 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010670 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,654.1201 F1 · shares: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. F2 · balance_after: Reflects 2,639.4168 shares of deferred common stock which vested on 1/20/2019 and were transferred to the Reporting Person's deferred compensation account in accordance with the terms of the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 36.2104 | $58.01 | $2,100.71 |
DisclosureSEC source: 0001209191-19-001877 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,692.8449 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 142.8498 | $58.01 | $8,287.29 |
DisclosureSEC source: 0001209191-19-001877 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,513.2375 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 21:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | ConversionSeries A Convertible Preferred Stock · Derivative | 14,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-055385 · doc4.xml · derivative · entry 3 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,870 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 21:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | ConversionCommon Stock | 74,870 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055385 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 21:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | PurchaseCommon Stock | 30,000 | $18.00 | $540,000.00 |
DisclosureSEC source: 0001209191-18-055385 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:03 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 29.6595 | $70.35 | $2,086.43 |
DisclosureSEC source: 0001209191-18-053744 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,656.6345 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:03 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 117.0064 | $70.35 | $8,230.93 |
DisclosureSEC source: 0001209191-18-053744 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,370.3877 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2018 Filed Jul 2, 2018 20:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 21.848 | $67.57 | $1,476.27 |
DisclosureSEC source: 0001209191-18-040284 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,626.975 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2018 Filed Jul 2, 2018 20:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 86.1906 | $67.57 | $5,823.90 |
DisclosureSEC source: 0001209191-18-040284 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,253.3813 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 20:03 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 11.1031 | $74.44 | $826.47 |
DisclosureSEC source: 0001209191-18-022843 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,605.127 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 20:03 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 77.8794 | $74.44 | $5,797.03 |
DisclosureSEC source: 0001209191-18-022843 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,167.1907 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 13:21 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 2,015.0457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-010634 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,594.0239 F1 · shares: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. F2 · balance_after: Reflects 4,135.7698 shares of deferred common stock which vested on 1/20/2018 and were transferred to the Reporting Person's deferred compensation account in accordance with the terms of the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:08 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 28.3209 | $75.63 | $2,142.02 |
DisclosureSEC source: 0001209191-18-000788 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,714.748 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:08 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 58.8524 | $75.63 | $4,451.24 |
DisclosureSEC source: 0001209191-18-000788 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,953.5415 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:24 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 8,810 | $88.79 Strike: $91.21 | $782,239.90 |
DisclosureSEC source: 0001209191-17-056235 · doc4.xml · derivative · entry 5 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,810 shares Expires 2027-06-19 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F7 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 20, 2017. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:24 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 7,000 | $129.13 Strike: $50.87 | $903,910.00 |
DisclosureSEC source: 0001209191-17-056235 · doc4.xml · derivative · entry 4 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2026-05-31 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F6 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 1, 2016. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:24 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 20,000 | $123.88 Strike: $56.12 | $2,477,600.00 |
DisclosureSEC source: 0001209191-17-056235 · doc4.xml · derivative · entry 3 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-09-08 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F4 · derivative.exercise_date: This option provided for vesting in 36 equal monthly installments commencing October 9, 2015. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:24 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerCommon Stock | 1,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-056235 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3 · price: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:24 UTC | Kite Pharma, Inc. KITE · Entity 172664 | OtherCommon Stock | 4,624 | $180.00 | $832,320.00 |
DisclosureSEC source: 0001209191-17-056235 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,807 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Read SEC document |
| October 01, 2017 Filed Oct 3, 2017 20:06 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 31.3762 | $67.95 | $2,131.89 |
DisclosureSEC source: 0001209191-17-055003 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,686.4271 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2017 Filed Oct 3, 2017 20:06 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 65.2013 | $67.95 | $4,430.17 |
DisclosureSEC source: 0001209191-17-055003 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,894.6891 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 20:04 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 16.9332 | $62.77 | $1,062.93 |
DisclosureSEC source: 0001209191-17-043226 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,655.0509 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 20:04 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 35.1878 | $62.77 | $2,208.81 |
DisclosureSEC source: 0001209191-17-043226 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,829.4878 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 14:39 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,810 | $0.00 Strike: $91.21 | $0.00 |
DisclosureSEC source: 0001209191-17-041306 · doc4.xml · derivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,810 Underlying: Common Stock · 8,810 shares Expires 2027-06-19 F1 · derivative.exercise_date: The stock option shall vest in 12 successive equal monthly installments following the date of grant. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 14:39 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GrantCommon Stock | 2,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041306 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,431 Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 20:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 10.6831 | $61.11 | $652.81 |
DisclosureSEC source: 0001209191-17-024668 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,638.1177 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 20:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 36.0432 | $61.11 | $2,202.49 |
DisclosureSEC source: 0001209191-17-024668 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,794.3 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 22:47 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 2,549.5462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012304 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,627.4346 F1 · shares: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. F2 · balance_after: Reflects 2,999.6090 shares of deferred common stock which vested on 1/20/2017 and were transferred to the Reporting Person's deferred compensation account in accordance with the terms of the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:09 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 29.279 | $58.65 | $1,717.30 |
DisclosureSEC source: 0001209191-17-001978 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,758.6478 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:09 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 19.2611 | $58.65 | $1,129.72 |
DisclosureSEC source: 0001209191-17-001978 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,077.4974 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 20:06 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 36.1701 | $47.31 | $1,711.35 |
DisclosureSEC source: 0001209191-16-144133 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,729.3688 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 20:06 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 23.7942 | $47.31 | $1,125.80 |
DisclosureSEC source: 0001209191-16-144133 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,058.2363 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 20:07 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 11.8664 | $45.02 | $534.19 |
DisclosureSEC source: 0001209191-16-131524 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,693.1987 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 20:07 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 7.8062 | $45.02 | $351.41 |
DisclosureSEC source: 0001209191-16-131524 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,034.4421 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2016 Filed Apr 5, 2016 20:07 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 12.6735 | $42.10 | $533.54 |
DisclosureSEC source: 0001209191-16-112938 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,681.3323 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2016 Filed Apr 5, 2016 20:07 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 3.5336 | $42.10 | $148.76 |
DisclosureSEC source: 0001209191-16-112938 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,026.6359 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.